GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adverum Biotechnologies Inc (LTS:0HA3) » Definitions » Cyclically Adjusted Book per Share

Adverum Biotechnologies (LTS:0HA3) Cyclically Adjusted Book per Share : $52.55 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Adverum Biotechnologies Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Adverum Biotechnologies's adjusted book value per share for the three months ended in Mar. 2024 was $8.783. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $52.55 for the trailing ten years ended in Mar. 2024.

During the past 12 months, Adverum Biotechnologies's average Cyclically Adjusted Book Growth Rate was -1.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-09), Adverum Biotechnologies's current stock price is $7.29. Adverum Biotechnologies's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $52.55. Adverum Biotechnologies's Cyclically Adjusted PB Ratio of today is 0.14.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Adverum Biotechnologies was 0.40. The lowest was 0.13. And the median was 0.20.


Adverum Biotechnologies Cyclically Adjusted Book per Share Historical Data

The historical data trend for Adverum Biotechnologies's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adverum Biotechnologies Cyclically Adjusted Book per Share Chart

Adverum Biotechnologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 54.13 52.10

Adverum Biotechnologies Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 58.43 51.94 54.07 52.10 52.55

Competitive Comparison of Adverum Biotechnologies's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Adverum Biotechnologies's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adverum Biotechnologies's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adverum Biotechnologies's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Adverum Biotechnologies's Cyclically Adjusted PB Ratio falls into.



Adverum Biotechnologies Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Adverum Biotechnologies's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=8.783/131.7762*131.7762
=8.783

Current CPI (Mar. 2024) = 131.7762.

Adverum Biotechnologies Quarterly Data

Book Value per Share CPI Adj_Book
201406 -7.945 100.560 -10.411
201409 69.307 100.428 90.941
201412 65.695 99.070 87.383
201503 109.791 99.621 145.229
201506 105.404 100.684 137.954
201509 101.852 100.392 133.693
201512 97.682 99.792 128.989
201603 89.155 100.470 116.935
201606 59.932 101.688 77.665
201609 56.625 101.861 73.255
201612 51.573 101.863 66.718
201703 47.073 102.862 60.305
201706 44.484 103.349 56.720
201709 41.591 104.136 52.630
201712 37.545 104.011 47.567
201803 39.536 105.290 49.482
201806 37.270 106.317 46.195
201809 34.309 106.507 42.449
201812 31.949 105.998 39.719
201903 29.706 107.251 36.499
201906 27.609 108.070 33.665
201909 25.427 108.329 30.930
201912 25.985 108.420 31.583
202003 38.052 108.902 46.045
202006 35.040 108.767 42.452
202009 47.679 109.815 57.214
202012 44.526 109.897 53.391
202103 42.360 111.754 49.949
202106 38.641 114.631 44.420
202109 35.255 115.734 40.142
202112 32.139 117.630 36.004
202203 28.648 121.301 31.122
202206 24.591 125.017 25.921
202209 20.891 125.227 21.984
202212 18.131 125.222 19.080
202303 15.686 127.348 16.231
202306 12.987 128.729 13.294
202309 10.167 129.860 10.317
202312 8.229 129.419 8.379
202403 8.783 131.776 8.783

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Adverum Biotechnologies  (LTS:0HA3) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Adverum Biotechnologies's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=7.29/52.55
=0.14

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 12 years, the highest Cyclically Adjusted PB Ratio of Adverum Biotechnologies was 0.40. The lowest was 0.13. And the median was 0.20.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Adverum Biotechnologies Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Adverum Biotechnologies's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Adverum Biotechnologies (LTS:0HA3) Business Description

Traded in Other Exchanges
Address
100 Cardinal Way, Redwood CIty, CA, USA, 94063
Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. It has one segment developing and commercializing gene therapeutics.

Adverum Biotechnologies (LTS:0HA3) Headlines

No Headlines